Formulation and optimization of oxaliplatin immuno-nanoparticles using Box–Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer
Source abstract
Abstract
Conventional chemotherapy majorly lacks clinical application attributed to its inspecificity, adverse effects and inability to penetrate into tumor cells. Hence, the aim of the study was to prepare oxaliplatin solid lipid nanoparticles (OP-SLN) by microemulsion method optimizing it by Box-Behnken design and then covalently conjugated to TRAIL (CD-253) monoclonal antibody (TR-OP-SLN) for targeting colorectal cancer cells. The optimized OP-SLN3 has shown an appreciable particle size (121 ± 1.22 nm), entrapment efficiency (78 ± 0.09%) and drug loading (32 ± 1.01%). Fluorescence study and the Bradford assay further confirmed the binding of the protein. A 1.5-fold increase in cytotoxicity of immuno-nanoparticles (4.9 μM) was observed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Protein Interaction Studies and Fluorescence Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. 10.3109/21691401.2015.102963310.3109/21691401.2015.1029633 ↗
2. 10.1016/0378-5173(94)00339-710.1016/0378-5173(94)00339-7 ↗
3. 10.1016/S0378-5173(96)04764-310.1016/S0378-5173(96)04764-3 ↗
4. 10.1016/j.jconrel.2010.02.02610.1016/j.jconrel.2010.02.026 ↗
5. 10.1007/978-0-387-73898-7_310.1007/978-0-387-73898-7_3 ↗
6. Domb AJ · Drugs Pharm Sci · 1996 · 73 · 377
7. 10.1007/s12195-011-0198-310.1007/s12195-011-0198-3 ↗
8. 10.1016/S0009-2509(03)00234-310.1016/S0009-2509(03)00234-3 ↗
9. 10.1016/j.ces.2007.08.00610.1016/j.ces.2007.08.006 ↗
10. 10.1016/B978-0-12-382239-0.00001-710.1016/B978-0-12-382239-0.00001-7 ↗
11. 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
12. 10.1016/j.ejphar.2009.06.06610.1016/j.ejphar.2009.06.066 ↗
13. 10.1016/S0378-5173(99)00256-210.1016/S0378-5173(99)00256-2 ↗
14. Jain A · J Pharm Pharm Sci · 2007 · 10 · 86
15. 10.1016/j.nano.2009.03.00210.1016/j.nano.2009.03.002 ↗
16. 10.3109/10717544.2014.88599910.3109/10717544.2014.885999 ↗
17. 10.1038/nrd268310.1038/nrd2683 ↗
18. 10.3109/21691401.2015.100851310.3109/21691401.2015.1008513 ↗
19. 10.1016/j.jconrel.2007.03.01210.1016/j.jconrel.2007.03.012 ↗
20. Krishnaiah Y · 2001 · 89
21. 10.1038/sj.cdd.440118710.1038/sj.cdd.4401187 ↗
22. 10.1038/nbt.154910.1038/nbt.1549 ↗
23. 10.3109/21691401.2015.104210810.3109/21691401.2015.1042108 ↗
24. 10.1016/j.carbpol.2012.12.03210.1016/j.carbpol.2012.12.032 ↗
25. 10.1016/j.semcancer.2005.06.00510.1016/j.semcancer.2005.06.005 ↗
26. 10.1200/JCO.2010.34.076010.1200/JCO.2010.34.0760 ↗
27. Mohideen B · Int J Biol Pharm Res · 2013 · 4 · 533
28. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
29. 10.1016/j.reactfunctpolym.2006.09.00110.1016/j.reactfunctpolym.2006.09.001 ↗
30. 10.2174/156800904348159710.2174/1568009043481597 ↗
31. Siekmann B · Pharm Pharmacol Lett · 1992 · 1 · 123
32. 10.1016/j.colsurfb.2013.09.03010.1016/j.colsurfb.2013.09.030 ↗
33. 10.1016/j.biomaterials.2006.05.01610.1016/j.biomaterials.2006.05.016 ↗
34. 10.1016/j.addr.2003.10.04010.1016/j.addr.2003.10.040 ↗
35. 10.1021/am406012g10.1021/am406012g ↗
36. 10.1038/551710.1038/5517 ↗
37. 10.1056/NEJMp110154810.1056/NEJMp1101548 ↗